Liquidia Technologies Price to Free Cash Flow Ratio 2018-2025 | LQDA

Liquidia Technologies price to free cash flow ratio from 2018 to 2025. Price to free cash flow ratio can be defined as

Liquidia Technologies Price to Free Cash Flow Ratio 2018-2025 | LQDA

Liquidia Technologies price to free cash flow ratio from 2018 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.1B
Amgen (AMGN)$157.3B
Gilead Sciences (GILD)$135.7B
Vertex Pharmaceuticals (VRTX)$119.2B
Bristol Myers Squibb (BMY)$94.5B
CSL (CSLLY)$78.8B
GSK (GSK)$77.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$40.6B
Argenex SE (ARGX)$34B
BioNTech SE (BNTX)$26.6B
Royalty Pharma (RPRX)$20.5B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$15.4B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.6B
Incyte (INCY)$13.2B
Moderna (MRNA)$12.2B
Exelixis (EXEL)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
Ascendis Pharma (ASND)$10.7B
QIAGEN (QGEN)$10.5B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$10B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.4B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.7B
Legend Biotech (LEGN)$7.3B